Abstract

More and more in-depth studies have revealed that the occurrence and development of tumors depend on gene mutation and tumor heterogeneity. The most important manifestation of tumor heterogeneity is the dynamic change of tumor microenvironment (TME) heterogeneity. This depends not only on the tumor cells themselves in the microenvironment where the infiltrating immune cells and matrix together forming an antitumor and/or pro-tumor network. TME has resulted in novel therapeutic interventions as a place beyond tumor beds. The malignant cancer cells, tumor infiltrate immune cells, angiogenic vascular cells, lymphatic endothelial cells, cancer-associated fibroblastic cells, and the released factors including intracellular metabolites, hormonal signals and inflammatory mediators all contribute actively to cancer progression. Protein post-translational modification (PTM) is often regarded as a degradative mechanism in protein destruction or turnover to maintain physiological homeostasis. Advances in quantitative transcriptomics, proteomics, and nuclease-based gene editing are now paving the global ways for exploring PTMs. In this review, we focus on recent developments in the PTM area and speculate on their importance as a critical functional readout for the regulation of TME. A wealth of information has been emerging to prove useful in the search for conventional therapies and the development of global therapeutic strategies.

Details

Title
Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment
Author
Li, Wen 1 ; Li, Feifei 2 ; Zhang, Xia 3 ; Hui-Kuan, Lin 4 ; Xu, Chuan 5   VIAFID ORCID Logo 

 University of Electronic Science and Technology of China, Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, Chengdu, P. R. China (GRID:grid.54549.39) (ISNI:0000 0004 0369 4060) 
 University of Electronic Science and Technology of China, Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, Chengdu, P. R. China (GRID:grid.54549.39) (ISNI:0000 0004 0369 4060); Guangxi Medical University, Guangxi Collaborative Innovation Center for Biomedicine (Guangxi-ASEAN Collaborative Innovation Center for Major Disease Prevention and Treatment), Nanning, China (GRID:grid.256607.0) (ISNI:0000 0004 1798 2653) 
 Third Military Medical University (Army Medical University), Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Chongqing, China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682) 
 Wake Forest University, Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318) 
 University of Electronic Science and Technology of China, Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, Chengdu, P. R. China (GRID:grid.54549.39) (ISNI:0000 0004 0369 4060); Wake Forest University, Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2611367917
Copyright
© The Author(s) 2021. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.